- Home
- GOOD vs NMRA Comparison
GOOD vs NMRA Comparison
Compare GOOD & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GOOD | NMRA |
|---|---|---|
| Founded | 2003 | 2019 |
| Country | United States | United States |
| Employees | 72 | N/A |
| Industry | Real Estate Investment Trusts | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 594.9M | 554.0M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | GOOD | NMRA |
|---|---|---|
| Price | $12.33 | $2.01 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 9 |
| Target Price | ★ $12.50 | $6.57 |
| AVG Volume (30 Days) | 385.3K | ★ 1.1M |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | ★ 9.80% | N/A |
| EPS Growth | N/A | ★ 5.23 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $10.37 | N/A |
| Revenue Next Year | $2.56 | N/A |
| P/E Ratio | $62.41 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.33 | $0.63 |
| 52 Week High | $14.70 | $3.65 |
Technical Indicators
Market Signals| Indicator | GOOD | NMRA |
|---|---|---|
| Relative Strength Index (RSI) | 63.88 | 34.19 |
| Support Level | $12.09 | $1.79 |
| Resistance Level | $13.44 | $2.20 |
| Average True Range (ATR) | 0.22 | 0.16 |
| MACD | 0.10 | -0.01 |
| Stochastic Oscillator | 97.54 | 24.53 |
Price Performance
Historical ComparisonAbout GOOD Gladstone Commercial Corporation Real Estate Investment Trust
Gladstone Commercial Corp is a real estate investment trust, which engages in investing and owning net leased industrial, commercial, and retail real property and making long-term industrial and commercial mortgage loans. Its portfolio consists of single-tenant commercial, industrial real properties, and medical properties nationwide. Its principal investment objectives are to generate income from rental properties.
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.